NCT03094429: An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults |
|
|
| Recruiting | 2/3 | 287 | US | NaBen®, Placebo | SyneuRx International (Taiwan) Corp, Amarex Clinical Research | Refractory Schizophrenia | 09/26 | 12/26 | | |